Metastatic Prostate Cancer

This e-course will comprise three presentations that provide comprehensive state-of-the-art information on currently available therapies for hormone-naïve prostate cancer (HNPC) and castration-resistant prostate cancer (CRPC).

Published Wed, 8 Nov 2023
E CourseProstate CancerOncologyADTHNPCEAU Education Office ESU
Organiser European School of Urology (ESU)
CME 1.00
Duration Approx. 60 minutes

The therapies will include androgen deprivation therapy (ADT) and androgen receptor pathway inhibitors (ARPI), chemotherapy, radioligand, and poly (ADP-ribose) polymerase (PARP) inhibitors.

The e-course aims to enable participants in optimising treatment combinations and sequences in metastatic prostate cancer at all disease stages.

Prof. B. Tombal (BE)
Dr. C. Thibault (FR)
Prof. Dr. C. Gratzke (DE)

Contact our organiser

European School of Urology (ESU)